06 July 2022

---

Orthocell Signs Striate+ Global Exclusive License and Manufacturing Agreement with BioHorizons

Regenerative medicine company Orthocell Limited is pleased to announce it has entered into an exclusive patent and trademark license agreement and an exclusive distribution and supply agreement with BioHorizons Implant Systems Inc.

---

The license relates to the Striate+ products for dental and oral-maxillofacial procedures (the field). The term of the license is linked to the term of the supply and distribution agreement (25 years) (Term). In consideration for the exclusive license, BioHorizons will pay Orthocell AU $23.1 million1 (USD $16 million) within two business days of the date of execution.

Commenting on the Agreements, President and CEO of BioHorizons, Steve Boggan, said: “We are very pleased to partner with Orthocell to offer our valued customers a dental membrane with excellent handling properties and regenerative potential. Striate+ will be a highly complementary addition to our global biomaterials product portfolio for dental tissue regeneration.”

Orthocell Managing Director Paul Anderson, said: “BioHorizons is a leading global provider of dental implant and tissue regenerative products with specialist capabilities and resources to expand the marketing, promotion, and supply of Striate+ worldwide. We are delighted to be working with BioHorizons which has established relationships with dentists and dental specialists and a successful track record in driving the market entry of high-quality products.

“The agreements with BioHorizons represent a significant milestone for Orthocell and provide further external commercial and technical validation of the CelGro collagen scaffold platform, from which the Striate+ dental products were developed.”

Striate+ is a market leading resorbable collagen membrane used in guided bone and tissue regeneration procedures. Its uptake is expected to be driven by surgeons’ preference for high quality, easy to use devices facilitating better patient outcomes. Clinical studies2 have shown Striate+ supported transition from two- stage to single-stage dental procedures, reducing the procedure time by several months. This is of significant interest to patients and clinicians due to potential improvements in efficiency and efficacy of dental procedures.

BioHorizons, Inc. is part of Henry Schein, Inc. (NASDAQ: HSIC) and a leading global provider of dental implants and tissue regeneration products for dentists and dental specialists. The company has a broad product offering, including dental implants, guided surgery, digital restorations, and tissue regeneration solutions for the replacement of missing teeth.

BioHorizons products are available in 90 markets around the world.

Source: www.biohorizons.com